{
    "clinical_study": {
        "@rank": "139414", 
        "acronym": "BASIC", 
        "arm_group": [
            {
                "arm_group_label": "A. FE 200440", 
                "arm_group_type": "Experimental", 
                "description": "Barusiban (FE 200440) Solution for Injection for Subcutaneous use"
            }, 
            {
                "arm_group_label": "B. Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Solution for Injection for Subcutaneous use"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial investigates the effects of FE 200440 compared to placebo on implantation rate in\n      women undergoing IVF/ICSI treatment"
        }, 
        "brief_title": "Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged 18-37 years\n\n          -  Women who have undergone 2-4 previous fresh in vitro fertilization (IVF) or\n             intracytoplasmatic sperm injection (ICSI) cycles that all resulted in a negative \u03b2hCG\n             test, despite transfer of at least one embryo/blastocyst of good quality\n\n          -  Women who have in the current controlled ovarian stimulation cycle for IVF/ICSI\n             followed the long Gonadotrophin Releasing Hormone (GnRH) agonist or GnRH antagonist\n             protocol, received hCG for triggering of final follicular maturation and have\n             undergone oocyte retrieval for IVF/ICSI with the purpose of fresh transfer\n\n          -  Retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle\n\n          -  Subjects should have at least one embryo of good quality available for transfer on\n             day 3, or at least one good quality blastocyst available for transfer on day 5\n\n        Exclusion Criteria:\n\n          -  A total of 6 or more controlled ovarian stimulation cycles for IVF/ICSI\n\n          -  Abnormal karyotype\n\n          -  Uterine pathology or hydrosalpinx\n\n          -  Diagnosed with acquired or congenital thrombophilia disease"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "37 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723982", 
            "org_study_id": "000048", 
            "secondary_id": "2012-001622-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "A. FE 200440", 
                "intervention_name": "Barusiban (FE 200440)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B. Placebo", 
                "intervention_name": "Placebo Comparator", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "Westmead Fertility Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Monash IVF"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Melbourne IVF"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Brussel"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "AZ Jan Palfijn Gent AV"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montr\u00e9al", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Clinique OVO"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "ICF CUBE"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "nOvum"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Alicante"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Dexeus"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Madrid"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Sevilla"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Valencia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Zaragoza"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Canada", 
                "Czech Republic", 
                "Poland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Australia: Human Research Ethics Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Belgium: Ethics Committee", 
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Central Register of Clinical Trials", 
                "Poland: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ongoing implantation rate", 
            "safety_issue": "No", 
            "time_frame": "10-11 weeks after embryo transfer"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723982"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "10-11 weeks after transfer"
            }, 
            {
                "measure": "Implantation rate", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after transfer"
            }, 
            {
                "measure": "Clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after transfer"
            }, 
            {
                "measure": "Positive Beta Human Chorionic Gonadotrophin (\u03b2hCG) rate", 
                "safety_issue": "No", 
                "time_frame": "13-15 days after transfer"
            }, 
            {
                "measure": "Serum barusiban concentration at the expected tmax", 
                "safety_issue": "No", 
                "time_frame": "30 min after 2nd IMP administration"
            }, 
            {
                "measure": "Frequency and intensity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 60 days of oocyte retrieval +1 day until 10 -11 weeks after embryo transfer"
            }, 
            {
                "measure": "Frequency and intensity of injection site reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Immediately and 30 min after each administration of IMP"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}